Literature DB >> 9211200

Assessment of homocysteine status.

H Refsum1, T Fiskerstrand, A B Guttormsen, P M Ueland.   

Abstract

Plasma total homocysteine (tHcy) determination is used in the diagnosis of homocystinuria, in cobalamin and folate deficiency and in cardiovascular risk assessment. However, determination of tHcy includes many pitfalls which complicate the assessment of homocysteine status. In the present article, we review basic knowledge for a rational use of plasma tHcy in diagnostic as well as scientific work. The subjects dealt with are procedures for sample handling and processing, the principles of tHcy analyses, and genetic and acquired determinants of the plasma tHcy concentration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9211200     DOI: 10.1023/a:1005321225893

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  54 in total

1.  Experimental basis of standardized specimen collection: effect of posture on blood picture.

Authors:  E A Leppänen; R Gräsbeck
Journal:  Eur J Haematol       Date:  1988-03       Impact factor: 2.997

2.  Effective homocysteine metabolism may protect South African blacks against coronary heart disease.

Authors:  J B Ubbink; W J Vermaak; R Delport; A van der Merwe; P J Becker; H Potgieter
Journal:  Am J Clin Nutr       Date:  1995-10       Impact factor: 7.045

3.  Homocysteine in plasma: stabilization of blood samples with fluoride.

Authors:  J Møller; K Rasmussen
Journal:  Clin Chem       Date:  1995-05       Impact factor: 8.327

4.  Homocystinuria. Clinical and dietary studies.

Authors:  D P Brenton; D C Cusworth; C E Dent; E E Jones
Journal:  Q J Med       Date:  1966-07

Review 5.  Clinical significance of pharmacological modulation of homocysteine metabolism.

Authors:  H Refsum; P M Ueland
Journal:  Trends Pharmacol Sci       Date:  1990-10       Impact factor: 14.819

Review 6.  Homocysteinemia and vascular disease in end-stage renal disease.

Authors:  V W Dennis; K Robinson
Journal:  Kidney Int Suppl       Date:  1996-12       Impact factor: 10.545

7.  Radioenzymic determination of homocysteine in plasma and urine.

Authors:  H Refsum; S Helland; P M Ueland
Journal:  Clin Chem       Date:  1985-04       Impact factor: 8.327

8.  Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia.

Authors:  A M Engbersen; D G Franken; G H Boers; E M Stevens; F J Trijbels; H J Blom
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

9.  Homocysteinemia due to folate deficiency.

Authors:  S S Kang; P W Wong; M Norusis
Journal:  Metabolism       Date:  1987-05       Impact factor: 8.694

10.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.

Authors:  C J Boushey; S A Beresford; G S Omenn; A G Motulsky
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

View more
  5 in total

Review 1.  ACP Broadsheet No 152: March 1998. Clinical implications of plasma homocysteine measurement in cardiovascular disease.

Authors:  R A Still; I F McDowell
Journal:  J Clin Pathol       Date:  1998-03       Impact factor: 3.411

2.  The factors that affect plasma homocysteine levels, pulse wave velocity and their relationship with cardiovascular disease indicators in peritoneal dialysis patients.

Authors:  Sibel Ertek; Ayse Nur Torun; Kenan Ates
Journal:  Int Urol Nephrol       Date:  2009-08-04       Impact factor: 2.370

3.  Hyperhomocysteinemia: An emerging risk factor for cardiovascular disease.

Authors:  V Govindaraju; C N Manjunath; H Venkataramiah; T R Raghu
Journal:  Indian J Clin Biochem       Date:  2003-01

4.  High homocysteine and blood pressure related to poor outcome of acute ischemia stroke in Chinese population.

Authors:  Chongke Zhong; Liying Lv; Changjiang Liu; Liang Zhao; Mo Zhou; Wenjie Sun; Tan Xu; Weijun Tong
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

5.  Therapeutical approach to plasma homocysteine and cardiovascular risk reduction.

Authors:  Marcello Ciaccio; Giulia Bivona; Chiara Bellia
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.